Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Autonomix Medical, Inc.AMIX · Entity 8309 | Director | September 03, 2026 | September 08, 2026 |
| Moleculin Biotech, Inc.MBRX · Entity 7886 | Director · CEO and President | August 03, 2026 | August 05, 2026 |
| Soliton, Inc.SOLY · Entity 132212 | Director · Executive Chairman | December 16, 2021 | December 17, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Autonomix Medical, Inc.
Report date September 03, 2026 · Filed September 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 20,118 |
Reported balance
After 2026-09-03 transaction · row 1
1 source rowRow 1 · 2026-09-03 · Grant · Acquired 13,000 · Balance 20,118 F1: Represents restricted stock award vesting one-year from the date of issuance of September 3, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock award vesting one-year from the date of issuance of September 3, 2026.
Moleculin Biotech, Inc.
Report date August 03, 2026 · Filed August 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 564,340 |
Reported balance
After 2026-08-03 transaction · row 1
1 source rowRow 1 · 2026-08-03 · Purchase · Acquired 533,333 · Balance 564,340 F1: On August 3, 2026, the reporting person acquired 533,333 shares of common stock and Series I warrants to purchase 1,599,999 shares of common stock at a combined purchase price of $0.75 per one share of common stock and three accompanying warrants in a public offering. |
| Series I WarrantsSEC Table II · derivative / convertible security · Expires 2031-08-03 | Direct | 1,926,335 |
Reported balance
After 2026-08-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-03 · Grant · Acquired 1,599,999 · Balance 1,926,335 F1: On August 3, 2026, the reporting person acquired 533,333 shares of common stock and Series I warrants to purchase 1,599,999 shares of common stock at a combined purchase price of $0.75 per one share of common stock and three accompanying warrants in a public offering. |
Filing footnotes · ownership attribution and instrument terms
F1: On August 3, 2026, the reporting person acquired 533,333 shares of common stock and Series I warrants to purchase 1,599,999 shares of common stock at a combined purchase price of $0.75 per one share of common stock and three accompanying warrants in a public offering.
Soliton, Inc.
Report date December 16, 2021 · Filed December 17, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-12-16 transaction · row 1
1 source rowRow 1 · 2021-12-16 · Disposition to issuer · Disposed 425,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of May 8, 2021 (the "Merger Agreement"), by and among Soliton, Inc. (the "Company"), AbbVie Inc. ("AbbVie") and Scout Merger Sub, Inc., a wholly owned subsidiary of AbbVie ("Merger Sub"), at the effective time of the merger of Merger Sub with and into the Company (the "Merger"), these shares of Company common stock were converted into the right to receive $22.60 in cash (the "Merger Consideration"), without interest. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.75 · Expires 2028-06-07 | Direct | 0 |
Reported balance
After 2021-12-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-12-16 · Disposition to issuer · Disposed 725,000 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding and unexercised option, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the Merger Consideration minus the exercise price that would be due in cash upon exercise of such option. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.75 · Expires 2029-02-04 | Direct | 0 |
Reported balance
After 2021-12-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-12-16 · Disposition to issuer · Disposed 84,500 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding and unexercised option, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the Merger Consideration minus the exercise price that would be due in cash upon exercise of such option. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.62 · Expires 2029-06-27 | Direct | 0 |
Reported balance
After 2021-12-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-12-16 · Disposition to issuer · Disposed 35,150 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding and unexercised option, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the Merger Consideration minus the exercise price that would be due in cash upon exercise of such option. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.71 · Expires 2030-02-04 | Direct | 0 |
Reported balance
After 2021-12-16 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-12-16 · Disposition to issuer · Disposed 89,300 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding and unexercised option, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the Merger Consideration minus the exercise price that would be due in cash upon exercise of such option. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.74 · Expires 2031-01-21 | Direct | 0 |
Reported balance
After 2021-12-16 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-12-16 · Disposition to issuer · Disposed 113,000 · Balance 0 F2: Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding and unexercised option, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the Merger Consideration minus the exercise price that would be due in cash upon exercise of such option. |
| Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.75 · Expires 2023-10-19 | Direct | 0 |
Reported balance
After 2021-12-16 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-12-16 · Disposition to issuer · Disposed 11,512 · Balance 0 F3: Pursuant to the Merger Agreement, at the effective time of the Merger, each outstanding and unexercised warrant, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the excess of (i) the number of shares of common stock subject to the warrant, multiplied by the Merger Consideration over (ii) the number of shares of common stock subject to the warrant, multiplied by the per share exercise price of such warrant. |
| Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.75 · Expires 2023-10-30 | Direct | 0 |
Reported balance
After 2021-12-16 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2021-12-16 · Disposition to issuer · Disposed 8,634 · Balance 0 F3: Pursuant to the Merger Agreement, at the effective time of the Merger, each outstanding and unexercised warrant, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the excess of (i) the number of shares of common stock subject to the warrant, multiplied by the Merger Consideration over (ii) the number of shares of common stock subject to the warrant, multiplied by the per share exercise price of such warrant. |
| Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.75 · Expires 2023-11-15 | Direct | 0 |
Reported balance
After 2021-12-16 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2021-12-16 · Disposition to issuer · Disposed 7,771 · Balance 0 F3: Pursuant to the Merger Agreement, at the effective time of the Merger, each outstanding and unexercised warrant, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the excess of (i) the number of shares of common stock subject to the warrant, multiplied by the Merger Consideration over (ii) the number of shares of common stock subject to the warrant, multiplied by the per share exercise price of such warrant. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of May 8, 2021 (the "Merger Agreement"), by and among Soliton, Inc. (the "Company"), AbbVie Inc. ("AbbVie") and Scout Merger Sub, Inc., a wholly owned subsidiary of AbbVie ("Merger Sub"), at the effective time of the merger of Merger Sub with and into the Company (the "Merger"), these shares of Company common stock were converted into the right to receive $22.60 in cash (the "Merger Consideration"), without interest.
F2: Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding and unexercised option, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the Merger Consideration minus the exercise price that would be due in cash upon exercise of such option.
F3: Pursuant to the Merger Agreement, at the effective time of the Merger, each outstanding and unexercised warrant, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the excess of (i) the number of shares of common stock subject to the warrant, multiplied by the Merger Consideration over (ii) the number of shares of common stock subject to the warrant, multiplied by the per share exercise price of such warrant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 03, 2026 Filed Sep 8, 2026 20:23 UTC | Autonomix Medical, Inc. AMIX · Entity 8309 | GrantCommon Stock | 13,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-26-029835 · rdgdoc.xml · nonDerivative · entry 1 KLEMP WALTER V · CIK 0000938419 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,118 F1 · price: Represents restricted stock award vesting one-year from the date of issuance of September 3, 2026. Read SEC document |
| August 03, 2026 Filed Aug 5, 2026 20:16 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | GrantSeries I Warrants · Derivative | 1,599,999 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-26-025928 · rdgdoc.xml · derivative · entry 2 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,926,335 Underlying: Common Stock · 1,599,999 shares Expires 2031-08-03 F1 · derivative.exercise_price: On August 3, 2026, the reporting person acquired 533,333 shares of common stock and Series I warrants to purchase 1,599,999 shares of common stock at a combined purchase price of $0.75 per one share of common stock and three accompanying warrants in a public offering. F1 · price: On August 3, 2026, the reporting person acquired 533,333 shares of common stock and Series I warrants to purchase 1,599,999 shares of common stock at a combined purchase price of $0.75 per one share of common stock and three accompanying warrants in a public offering. F1 · balance_after: On August 3, 2026, the reporting person acquired 533,333 shares of common stock and Series I warrants to purchase 1,599,999 shares of common stock at a combined purchase price of $0.75 per one share of common stock and three accompanying warrants in a public offering. Read SEC document |
| August 03, 2026 Filed Aug 5, 2026 20:16 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | PurchaseCommon Stock | 533,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-26-025928 · rdgdoc.xml · nonDerivative · entry 1 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 564,340 F1 · price: On August 3, 2026, the reporting person acquired 533,333 shares of common stock and Series I warrants to purchase 1,599,999 shares of common stock at a combined purchase price of $0.75 per one share of common stock and three accompanying warrants in a public offering. Read SEC document |
| June 22, 2026 Filed Jun 25, 2026 01:00 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | Exercise / conversionRestricted Stock Units · Derivative | 360 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-021611 · rdgdoc.xml · derivative · entry 6 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 326,336 Underlying: Common Stock · 360 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: On June 22, 2023, the reporting person was granted 1,439 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F4 · derivative.expiration_date: On June 22, 2023, the reporting person was granted 1,439 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F5 · balance_after: Includes 250,002 shares of common stock underlying Series E warrants to purchase common stock. Read SEC document |
| June 22, 2026 Filed Jun 25, 2026 01:00 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | Tax withholdingCommon Stock | 88 | $3.12 | $274.56 |
DisclosureSEC source: 0001437749-26-021611 · rdgdoc.xml · nonDerivative · entry 4 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,007 F2 · shares: Shares withheld for payment of taxes upon vesting of restricted stock unit awards. Read SEC document |
| June 22, 2026 Filed Jun 25, 2026 01:00 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | Exercise / conversionCommon Stock | 360 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-26-021611 · rdgdoc.xml · nonDerivative · entry 3 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,088 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| June 20, 2026 Filed Jun 25, 2026 01:00 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | Exercise / conversionRestricted Stock Units · Derivative | 150 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-021611 · rdgdoc.xml · derivative · entry 5 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 326,696 Underlying: Common Stock · 150 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On June 20, 2022, the reporting person was granted 600 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F3 · derivative.expiration_date: On June 20, 2022, the reporting person was granted 600 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F5 · balance_after: Includes 250,002 shares of common stock underlying Series E warrants to purchase common stock. Read SEC document |
| June 20, 2026 Filed Jun 25, 2026 01:00 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | Tax withholdingCommon Stock | 37 | $2.88 | $106.56 |
DisclosureSEC source: 0001437749-26-021611 · rdgdoc.xml · nonDerivative · entry 2 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,728 F2 · shares: Shares withheld for payment of taxes upon vesting of restricted stock unit awards. Read SEC document |
| June 20, 2026 Filed Jun 25, 2026 01:00 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | Exercise / conversionCommon Stock | 150 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-26-021611 · rdgdoc.xml · nonDerivative · entry 1 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,765 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| November 12, 2025 Filed Nov 14, 2025 21:07 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | GrantPerformance Based Restricted Stock Units · Derivative | 750,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-25-035182 · rdgdoc.xml · derivative · entry 2 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,960,731 Underlying: Common Stock · 750,000 shares Expires 2035-11-12 F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one shares of Company common stock. F2 · price: Issued in connection with the reporting person's employment with the Company. F4 · derivative.exercise_date: On November 12, 2025, the Board approved this performance based restricted stock unit. The performance based restricted stock units set forth in this table will vest in 20% installments upon the achievement of certain clinical milestones; provided that upon a change of control (as defined in the 2024 Stock Plan) 100% shall vest. Read SEC document |
| November 12, 2025 Filed Nov 14, 2025 21:07 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | GrantStock option (right to buy) · Derivative | 830,000 | Not disclosed Strike: $0.49 | Not disclosed |
DisclosureSEC source: 0001437749-25-035182 · rdgdoc.xml · derivative · entry 1 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,210,731 Underlying: Common Stock · 830,000 shares Expires 2035-11-12 F2 · price: Issued in connection with the reporting person's employment with the Company. F1 · derivative.exercise_date: The stock option set forth in this table vests in four equal annual installments beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service to the Company on each vesting date. Read SEC document |
| November 04, 2025 Filed Nov 7, 2025 01:24 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | Exercise / conversionRestricted Stock Units · Derivative | 28,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-033683 · rdgdoc.xml · derivative · entry 3 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,380,731 Underlying: Common Stock · 28,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On November 4, 2024, the reporting person was granted 115,000 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F3 · derivative.expiration_date: On November 4, 2024, the reporting person was granted 115,000 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| November 04, 2025 Filed Nov 7, 2025 01:24 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | Tax withholdingCommon Stock | 7,001 | $0.50 | $3,479.50 |
DisclosureSEC source: 0001437749-25-033683 · rdgdoc.xml · nonDerivative · entry 2 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 765,356 F2 · shares: Shares withheld for payment of taxes upon vesting of restricted stock unit awards. Read SEC document |
| November 04, 2025 Filed Nov 7, 2025 01:24 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | Exercise / conversionCommon Stock | 28,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-25-033683 · rdgdoc.xml · nonDerivative · entry 1 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 772,357 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| August 11, 2025 Filed Aug 14, 2025 01:13 UTC | Autonomix Medical, Inc. AMIX · Entity 8309 | Disposition to issuerOption (Right to buy) · Derivative | 8,773 | Not disclosed Strike: $26.56 | Not disclosed |
DisclosureSEC source: 0001437749-25-026638 · rdgdoc.xml · derivative · entry 1 KLEMP WALTER V · CIK 0000938419 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,250 Underlying: Common Stock · 8,773 shares Expires 2034-06-21 F1 · derivative.exercise_price: Option represents a revised share amount and exercise price based on a 1-for-20 reverse stock split from October 25, 2024. The option was cancelled by mutual agreement of the reporting person and the Company. The reporting person received no consideration for the cancellation. F1 · shares: Option represents a revised share amount and exercise price based on a 1-for-20 reverse stock split from October 25, 2024. The option was cancelled by mutual agreement of the reporting person and the Company. The reporting person received no consideration for the cancellation. F1 · price: Option represents a revised share amount and exercise price based on a 1-for-20 reverse stock split from October 25, 2024. The option was cancelled by mutual agreement of the reporting person and the Company. The reporting person received no consideration for the cancellation. F2 · balance_after: Amount represents a revised share amount based on a 1-for-20 reverse stock split from October 25,2024. Read SEC document |
| June 23, 2025 Filed Jun 23, 2025 20:35 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | PurchaseSeries E Warrants · Derivative | 2,027,025 | Not disclosed Strike: $0.37 | Not disclosed |
DisclosureSEC source: 0001437749-25-021050 · rdgdoc.xml · derivative · entry 8 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,409,481 Underlying: Common Stock · 2,027,025 shares Expires not disclosed F5 · price: On June 23, 2025, the reporting person acquired 675,675 shares of common stock and Series E warrants to purchase 2,027,025 shares of common stock at a purchase price of $0.37 per share and accompanying warrants in a public offering. The Series E warrants will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the Series E warrants and will expire five years from the date of such approval. F5 · derivative.exercise_date: On June 23, 2025, the reporting person acquired 675,675 shares of common stock and Series E warrants to purchase 2,027,025 shares of common stock at a purchase price of $0.37 per share and accompanying warrants in a public offering. The Series E warrants will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the Series E warrants and will expire five years from the date of such approval. F5 · derivative.expiration_date: On June 23, 2025, the reporting person acquired 675,675 shares of common stock and Series E warrants to purchase 2,027,025 shares of common stock at a purchase price of $0.37 per share and accompanying warrants in a public offering. The Series E warrants will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the Series E warrants and will expire five years from the date of such approval. Read SEC document |
| June 23, 2025 Filed Jun 23, 2025 20:35 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | PurchaseCommon Stock | 675,675 | $0.37 | $249,999.75 |
DisclosureSEC source: 0001437749-25-021050 · rdgdoc.xml · nonDerivative · entry 5 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 743,607 F5 · price: On June 23, 2025, the reporting person acquired 675,675 shares of common stock and Series E warrants to purchase 2,027,025 shares of common stock at a purchase price of $0.37 per share and accompanying warrants in a public offering. The Series E warrants will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the Series E warrants and will expire five years from the date of such approval. Read SEC document |
| June 22, 2025 Filed Jun 23, 2025 20:35 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | Exercise / conversionRestricted Stock Units · Derivative | 8,990 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-021050 · rdgdoc.xml · derivative · entry 7 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 382,456 Underlying: Common Stock · 8,990 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: On June 22, 2023, the reporting person was granted 35,959 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F4 · derivative.expiration_date: On June 22, 2023, the reporting person was granted 35,959 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| June 22, 2025 Filed Jun 23, 2025 20:35 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | Tax withholdingCommon Stock | 2,190 | $0.27 | $584.73 |
DisclosureSEC source: 0001437749-25-021050 · rdgdoc.xml · nonDerivative · entry 4 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,932 F2 · shares: Shares withheld for payment of taxes upon vesting of restricted stock unit awards. Read SEC document |
| June 22, 2025 Filed Jun 23, 2025 20:35 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | Exercise / conversionCommon Stock | 8,990 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-25-021050 · rdgdoc.xml · nonDerivative · entry 3 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,122 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| June 20, 2025 Filed Jun 23, 2025 20:35 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | Exercise / conversionRestricted Stock Units · Derivative | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-021050 · rdgdoc.xml · derivative · entry 6 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 391,446 Underlying: Common Stock · 3,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On June 20, 2022, the reporting person was granted 15,000 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F3 · derivative.expiration_date: On June 20, 2022, the reporting person was granted 15,000 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| June 20, 2025 Filed Jun 23, 2025 20:35 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | Tax withholdingCommon Stock | 914 | $0.27 | $244.04 |
DisclosureSEC source: 0001437749-25-021050 · rdgdoc.xml · nonDerivative · entry 2 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,132 F2 · shares: Shares withheld for payment of taxes upon vesting of restricted stock unit awards. Read SEC document |
| June 20, 2025 Filed Jun 23, 2025 20:35 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | Exercise / conversionCommon Stock | 3,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-25-021050 · rdgdoc.xml · nonDerivative · entry 1 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,046 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| June 16, 2025 Filed Jun 19, 2025 01:00 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | Exercise / conversionRestricted Stock Units · Derivative | 1,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-020802 · rdgdoc.xml · derivative · entry 3 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 370,075 Underlying: Common Stock · 1,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On June 16, 2021, the reporting person was granted 6,668 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F3 · derivative.expiration_date: On June 16, 2021, the reporting person was granted 6,668 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| June 16, 2025 Filed Jun 19, 2025 01:00 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | Tax withholdingCommon Stock | 406 | $0.69 | $278.19 |
DisclosureSEC source: 0001437749-25-020802 · rdgdoc.xml · nonDerivative · entry 2 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,296 F2 · shares: Shares withheld for payment of taxes upon vesting of restricted stock unit awards Read SEC document |
| June 16, 2025 Filed Jun 19, 2025 01:00 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | Exercise / conversionCommon Stock | 1,667 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-25-020802 · rdgdoc.xml · nonDerivative · entry 1 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,702 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| November 04, 2024 Filed Nov 7, 2024 01:00 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | GrantRestricted Stock Units · Derivative | 115,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-24-033703 · rdgdoc.xml · derivative · entry 2 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 328,152 Underlying: Common Stock · 115,000 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one shares of Company common stock. F2 · price: Issued in connection with the reporting person's employment with the Company. F4 · derivative.exercise_date: The restricted stock units set forth in this table vests in four equal annual installments beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service to the Company on each vesting date. F4 · derivative.expiration_date: The restricted stock units set forth in this table vests in four equal annual installments beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service to the Company on each vesting date. Read SEC document |
| November 04, 2024 Filed Nov 7, 2024 01:00 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | GrantStock option (right to buy) · Derivative | 100,000 | Not disclosed Strike: $2.45 | Not disclosed |
DisclosureSEC source: 0001437749-24-033703 · rdgdoc.xml · derivative · entry 1 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 213,152 Underlying: Common Stock · 100,000 shares Expires 2024-11-04 F2 · price: Issued in connection with the reporting person's employment with the Company. F1 · derivative.exercise_date: The stock option set forth in this table vests in four equal annual installments beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service to the Company on each vesting date. Read SEC document |
| October 25, 2024 Filed Nov 7, 2024 01:00 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | GrantPerformance Based Restricted Stock Units · Derivative | 43,590 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-24-033703 · rdgdoc.xml · derivative · entry 3 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 371,742 Underlying: Common Stock · 43,590 shares Expires 2033-12-29 F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one shares of Company common stock. F2 · price: Issued in connection with the reporting person's employment with the Company. F5 · derivative.exercise_date: On December 29, 2023, the Board approved this performance based restricted stock unit, subject to shareholder approval of the stock plan. The performance based restricted stock units set forth in this table will vest only upon both (A) the approval of the Plan Amendment by the Company stockholders; and (B) the first of the following to occur: (a) a licensing transaction with a valuation, at the time, in excess of $150 million, which valuation shall be determined by the Board; (b) the filing of a new drug application; or (c) upon a Change in Control (as defined in the Plan), in each case subject to the respective executive officer's continued service with the Company at each such vesting date. Read SEC document |
| July 02, 2024 Filed Jul 5, 2024 21:01 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | Exercise / conversionRestricted Stock Units · Derivative | 982 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-022252 · rdgdoc.xml · derivative · entry 3 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,152 Underlying: Common Stock · 982 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On July 2, 2020, the reporting person was granted 3,926 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F3 · derivative.expiration_date: On July 2, 2020, the reporting person was granted 3,926 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| July 02, 2024 Filed Jul 5, 2024 21:01 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | Tax withholdingCommon Stock | 240 | $3.57 | $856.80 |
DisclosureSEC source: 0001437749-24-022252 · rdgdoc.xml · nonDerivative · entry 2 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,035 F2 · shares: Shares withheld for payment of taxes upon vesting of restricted stock unit awards. Read SEC document |
| July 02, 2024 Filed Jul 5, 2024 21:01 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | Exercise / conversionCommon Stock | 982 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-24-022252 · rdgdoc.xml · nonDerivative · entry 1 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,275 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| June 22, 2024 Filed Jun 25, 2024 22:00 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | Exercise / conversionRestricted Stock Units · Derivative | 8,990 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-021197 · rdgdoc.xml · derivative · entry 3 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,134 Underlying: Common Stock · 8,990 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On June 22, 2023, the reporting person was granted 35,959 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F3 · derivative.expiration_date: On June 22, 2023, the reporting person was granted 35,959 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| June 22, 2024 Filed Jun 25, 2024 22:00 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | Tax withholdingCommon Stock | 2,190 | $3.74 | $8,190.60 |
DisclosureSEC source: 0001437749-24-021197 · rdgdoc.xml · nonDerivative · entry 2 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,293 F2 · shares: Shares withheld for payment of taxes upon vesting of restricted stock unit awards. Read SEC document |
| June 22, 2024 Filed Jun 25, 2024 22:00 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | Exercise / conversionCommon Stock | 8,990 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-24-021197 · rdgdoc.xml · nonDerivative · entry 1 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,483 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| June 21, 2024 Filed Jun 24, 2024 21:09 UTC | Autonomix Medical, Inc. AMIX · Entity 8309 | GrantOption (Right to buy) · Derivative | 175,452 | Not disclosed Strike: $1.33 | Not disclosed |
DisclosureSEC source: 0001437749-24-021105 · rdgdoc.xml · derivative · entry 1 KLEMP WALTER V · CIK 0000938419 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,452 Underlying: Common Stock · 175,452 shares Expires 2034-06-21 F2 · price: Issued in connection with the reporting person's employment with the Company F1 · derivative.exercise_date: The option set forth in this table vests in four annual installments beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service to the Company on each vesting date. Read SEC document |
| June 20, 2024 Filed Jun 21, 2024 21:00 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | Exercise / conversionRestricted Stock Units · Derivative | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-020995 · rdgdoc.xml · derivative · entry 3 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,124 Underlying: Common Stock · 3,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On June 20, 2022, the reporting person was granted 15,000 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F3 · derivative.expiration_date: On June 20, 2022, the reporting person was granted 15,000 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| June 20, 2024 Filed Jun 21, 2024 21:00 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | Tax withholdingCommon Stock | 914 | $3.78 | $3,454.92 |
DisclosureSEC source: 0001437749-24-020995 · rdgdoc.xml · nonDerivative · entry 2 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,493 F2 · shares: Shares withheld for payment of taxes upon vesting of restricted stock unit awards. Read SEC document |
| June 20, 2024 Filed Jun 21, 2024 21:00 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | Exercise / conversionCommon Stock | 3,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-24-020995 · rdgdoc.xml · nonDerivative · entry 1 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,407 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| June 16, 2024 Filed Jun 18, 2024 21:01 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | Exercise / conversionRestricted Stock Units · Derivative | 1,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-020663 · rdgdoc.xml · derivative · entry 3 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,874 Underlying: Common Stock · 1,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On June 16, 2021, the reporting person was granted 6,668 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F3 · derivative.expiration_date: On June 16, 2021, the reporting person was granted 6,668 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| June 16, 2024 Filed Jun 18, 2024 21:01 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | Tax withholdingCommon Stock | 406 | $4.14 | $1,680.84 |
DisclosureSEC source: 0001437749-24-020663 · rdgdoc.xml · nonDerivative · entry 2 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,657 F2 · shares: Shares withheld for payment of taxes upon vesting of restricted stock unit awards. Read SEC document |
| June 16, 2024 Filed Jun 18, 2024 21:01 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | Exercise / conversionCommon Stock | 1,667 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-24-020663 · rdgdoc.xml · nonDerivative · entry 1 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| December 26, 2023 Filed Dec 27, 2023 12:31 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | PurchaseCommon Stock | 188,404 | $0.69 | $129,998.76 |
DisclosureSEC source: 0001437749-23-035340 · rdgdoc.xml · nonDerivative · entry 1 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 680,880 Read SEC document |
| July 11, 2023 Filed Jul 13, 2023 22:35 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | Exercise / conversionRestricted Stock Units · Derivative | 13,204 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-019907 · rdgdoc.xml · derivative · entry 3 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,928,145 Underlying: Common Stock · 13,204 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On July 11, 2019, the reporting person was granted 52,818 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F3 · derivative.expiration_date: On July 11, 2019, the reporting person was granted 52,818 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| July 11, 2023 Filed Jul 13, 2023 22:35 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | Tax withholdingCommon Stock | 3,216 | $0.59 | $1,898.40 |
DisclosureSEC source: 0001437749-23-019907 · rdgdoc.xml · nonDerivative · entry 2 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 492,476 F2 · shares: Shares withheld for payment of taxes upon vesting of restricted stock unit awards. Read SEC document |
| July 11, 2023 Filed Jul 13, 2023 22:35 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | Exercise / conversionCommon Stock | 13,204 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-23-019907 · rdgdoc.xml · nonDerivative · entry 1 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 495,692 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| July 02, 2023 Filed Jul 5, 2023 22:00 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | Exercise / conversionRestricted Stock Units · Derivative | 14,717 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-019412 · rdgdoc.xml · derivative · entry 3 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,941,349 Underlying: Common Stock · 14,717 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On July 2, 2020, the reporting person was granted 58,869 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F3 · derivative.expiration_date: On July 2, 2020, the reporting person was granted 58,869 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| July 02, 2023 Filed Jul 5, 2023 22:00 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | Tax withholdingCommon Stock | 3,584 | $0.58 | $2,074.42 |
DisclosureSEC source: 0001437749-23-019412 · rdgdoc.xml · nonDerivative · entry 2 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 482,488 F2 · shares: Shares withheld for payment of taxes upon vesting of restricted stock unit awards. Read SEC document |
| July 02, 2023 Filed Jul 5, 2023 22:00 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | Exercise / conversionCommon Stock | 14,717 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-23-019412 · rdgdoc.xml · nonDerivative · entry 1 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 486,072 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| June 22, 2023 Filed Jun 26, 2023 22:20 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | GrantRestricted Stock Units · Derivative | 539,375 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-23-018529 · rdgdoc.xml · derivative · entry 2 KLEMP WALTER V · CIK 0000938419 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,956,066 Underlying: Common Stock · 539,375 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one shares of Company common stock. F2 · price: Issued in connection with the reporting person's employment with the Company.Issued in connection with the reporting person's employment with the Company. F4 · derivative.exercise_date: The restricted stock units set forth in this table vests in four equal annual installments beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service to the Company on each vesting date. F4 · derivative.expiration_date: The restricted stock units set forth in this table vests in four equal annual installments beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service to the Company on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.